34 completed, 12 recruiting, 7 terminated, 6 unknown. 66 Phase 2, 19 Phase 1, 2 Phase 3.
Follow Sarcoma, Synovial: new trials by email Literature Review of Sarcoma, Synovial trials Research Report on Sarcoma, Synovial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Biopsy Procedure, Biospecimen Collection - Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 42 | 2026-11-23 | 2026-09-25 |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma preoperative, Quality of life, Functional outcome - Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 110 | 2026-01-26 | 2026-01-28 |
| Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas CD146/HER2 CAR-T cells - Sarcoma, Sarcoma, Kaposi | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2025-05-29 | 2025-07-15 |
| Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor Signifor - Desmoplastic Small Round Cell Tumor, Synovial Sarcoma | Phase 2 | Recruiting | University Hospital Heidelberg | 28 | 2024-12-19 | 2025-01-13 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma Biospecimen Collection, Computed Tomography, Echocardiography - Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma | Phase 2 | Recruiting | Northwestern University | 73 | 2024-09-19 | 2026-10-13 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) Peptide vaccine IPX - Ewing Sarcoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University Hospital Tuebingen | 30 | 2023-09-19 | 2026-05-04 |
| SPEARHEAD-3 Pediatric Study Afamitresgene autoleucel - Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) | Phase 1 / Phase 2 | Recruiting | USWM CT, LLC | 20 | 2023-09-01 | 2026-08-11 |
| Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT - Sarcoma, Synovial, Sarcoma,Soft Tissue | Phase 1 / Phase 2 | Recruiting | Hadassah Medical Organization | 3 | 2022-04-01 | 2025-10-02 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma Ramucirumab, Gemcitabine, Docetaxel - Synovial Sarcoma | Phase 1 / Phase 2 | Terminated | Eli Lilly and Company | 23 | 2020-03-04 | 2023-09-13 |
| Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide - Neoplasms | Phase 2 | Active not recruiting | USWM CT, LLC | 103 | 2019-12-31 | 2026-08-11 |
| Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma afamitresgene autoleucel (previously ADP-A2M4) - Synovial Sarcoma, Myxoid Liposarcoma | Phase 2 | Active not recruiting | USWM CT, LLC | 52 | 2019-08-13 | 2026-08-26 |
| APX005M and Doxorubicin in Advanced Sarcoma Doxorubicin, APX005M - Soft Tissue Sarcoma | Phase 2 | Completed | Alexander Z. Wei, MD | 27 | 2019-03-20 | 2026-06-10 |
| Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a GSK3377794, Pembrolizumab, Fludarabine - Neoplasms | Phase 2 | Withdrawn | GlaxoSmithKline | 2019-02-25 | 2019-10-29 |
Showing 20 of 66. Sign in to see all of them.
Sarcoma (49) · Leiomyosarcoma (38) · Histiocytoma, Malignant Fibrous (30) · Liposarcoma (29) · Neurofibrosarcoma (28) · Fibrosarcoma (23) · Hemangiosarcoma (23) · Rhabdomyosarcoma (23) · Osteosarcoma (16) · Sarcoma, Alveolar Soft Part (16) · Dermatofibrosarcoma (12) · Hemangiopericytoma, Malignant (10) · Malignant mesenchymal tumor (10) · Chondrosarcoma, Extraskeletal Myxoid (9)
Neoplasms by Histologic Type (66) · Neoplasms, Connective Tissue (66) · Neoplasms, Connective and Soft Tissue (65) · Neoplasms (64) · Neoplasms, Muscle Tissue (43) · Neoplasms, Fibrous Tissue (37) · Neoplasms, Nerve Tissue (36) · Neoplasms, Adipose Tissue (32) · Histiocytoma (30) · Nervous System Diseases (30) · Nervous System Neoplasms (30) · Neuromuscular Diseases (29) · Peripheral Nervous System Diseases (29) · Peripheral Nervous System Neoplasms (29) · Neurofibroma (28)
Doxorubicin (8) · Cyclophosphamide (5) · pazopanib (5) · Gemcitabine (4) · Ifosfamide (4) · Docetaxel (3) · Imatinib Mesylate (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Dacarbazine (2) · Injections (2) · Radiation Dose Hypofractionation (2) · Radiotherapy (2) · Sorafenib (2) · Specimen Handling (2) · Sunitinib (2)
National Cancer Institute (NCI) (10) · European Organisation for Research and Treatment of Cancer - EORTC (8) · Memorial Sloan Kettering Cancer Center (3) · USWM CT, LLC (3) · Brown University (2) · Eli Lilly and Company (2) · Epizyme, Inc. (2) · GlaxoSmithKline (2) · Maria Sklodowska-Curie National Research Institute of Oncology (2) · Oslo University Hospital (2) · Alexander Z. Wei, MD (1) · Children's Oncology Group (1) · Daiichi Sankyo (1) · Essen Biotech (1) · Fundación de investigación HM (1)
United States (38) · Belgium (11) · France (11) · United Kingdom (11) · Netherlands (9) · Germany (8) · Spain (7) · Canada (6) · Australia (5) · Poland (5) · Italy (4) · China (3) · Denmark (3) · Hungary (2) · Japan (2)
Ivar Hompland, MD, PhD (2) · Kjetil Boye, MD, PhD (2) · Aaron R Weiss (1) · Alba Rubio (1) · Alexander Wei, MD (1) · Antonio Casado (1) · Axel Le Cesne, MD (1) · Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Brenda Weigel, MD (1)
PMID 31401903, PMID 32827353, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17336054, PMID 18448563, PMID 19088049, PMID 19451429, PMID 19451433, PMID 20471824, PMID 20932656, PMID 22682017, PMID 23382028, PMID 23554566, PMID 24215845, PMID 24504442, PMID 30410720, PMID 32002290, PMID 32269142, PMID 32702309, PMID 33035459, PMID 33203665, PMID 34260265, PMID 34515544, PMID 35934010, PMID 37523624, PMID 39356980, PMID 40934647, PMID 41836677, PMID 42194972
P30CA008748 (4), U10CA098543 (3), 2015 (2), N01CM62206 (2), U01CA069856 (2), U10CA180886 (2), 2009 (1), 2018 (1), 2023 (1), N01CM62201 (1), P30CA012197 (1), P30CA015704 (1), P30CA016056 (1), P30CA060553 (1), R01CA164333 (1)